Best of Hematology and Breast Cancer 2026 - Portland
In-Person Event
Feb 06 - 07, 2026
Portland, Oregon, USA
8.5 AMA PRA Category 1 Credits™ ...Speakers
OVERVIEW
Best of Hematology and Breast Cancer 2026 is organized by Binaytara Foundation (BTF) and will be held from Feb 06 - 07, 2026 at Embassy Suites by Hilton Portland Downtown, Portland, Oregon, United States of America.
Description:
The Best of Hematology and Breast Cancer 2026, Portland is a CME/CE-accredited, in-person cancer conference. This annual hematology and oncology conference brings together physicians, nurses, pharmacists, and other healthcare professionals to review the most recent advancements in the management of hematologic malignancies and breast cancer.
This two-day oncology symposium delivers high-impact updates that can be directly applied to clinical practice. Through a dynamic mix of didactic lectures, case-based discussions, tumor board-style reviews, and interactive debates, participants will explore evolving standards of care, new treatment strategies, and real-world applications for improving outcomes.
By emphasizing a multidisciplinary approach, the program is designed not only for oncologists and hematologists but also for physician assistants, nurse practitioners, pharmacists, nurses, and all members of the cancer care team. In addition, networking breaks, exhibits, and receptions offer opportunities to collaborate with peers, learn from thought leaders, and connect with industry partners.
Conference Highlights
- Accreditation: CE credits for physicians, nurses, and pharmacists.
- Interactive Learning: A blend of lectures, case-based sessions and tumor-board style discussions.
- Multidisciplinary Focus: Relevant content for the entire oncology care team.
- Practical Insights: Strategies that connect clinical trial evidence to everyday patient care.
- Networking Opportunities: Dedicated time for exhibits, receptions, and peer engagement.
Learning Objectives:
Upon successful completion of this educational activity, participants will be able to:
- Summarize the latest updates from ASH25 and SABCS25, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
- Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH25 and SABCS25.
- Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH25 and SABCS25 that have influenced current standards of care.
- Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH25 and SABCS25 into patient management for hematologic disorders and breast cancer.
- Apply emerging data from clinical trials and updated expert guidelines from ASH25 and SABCS25 to individualize patient management strategies.
KEY DATES
06 Feb, 2026
Event Start Date
07 Feb, 2026
Event End Date
ACCREDITATION & CREDITS
Accreditation
8.50 AMA PRA Category 1 Credit™
The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 8.50 Best of Hematology & Breast Cancer 2026, Portland. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
8.50 ABIM MOC II
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
8.50 ACPE Pharmacy
The Binaytara is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to the activity is Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Best of Hematology & Breast Cancer 2026, Portland activity will not be awarded the CEUs. The Binaytara may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®. After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
8.50 Nursing Contact Hours
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantSurgeonsOncologistsNursesNurse PractitionersOther Health ProfessionalsRadiation OncologistsSPECIALITIES
HematologySurgical OncologySUGGESTED HOTELS
CONFERENCE VENUE
Embassy Suites by Hilton Portland Downtown
Quick Links